---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020832"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2024-05-21T23:59:59+00:00"
generated_at: "2026-06-01T11:17:26.700924+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Celularity guides Q4 2023 revenue ~$12.1M, Q1 2024 revenue ~$14.8M

## Summary
- Preliminary Q4 2023 net revenue ~$12.1M from biomaterial product sales and biobanking services.
- Preliminary Q1 2024 net revenue ~$14.8M from the same segments, up ~22% sequentially.
- Full-year 2023 and Q1 2024 financials not yet finalized; subject to audit/review adjustments.
- Company hosted an Investor & R&D Day on May 21, 2024, with presentation posted on IR website.

## SEC filing metadata
- accession: 0001493152-24-020832
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2024-05-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000149315224020832/0001493152-24-020832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000149315224020832/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020832
- JSON: https://secwatch.observer/filing/0001493152-24-020832.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.